Safety of Varenicline Among Smokers Enrolled in the Lung HIV Study
Nicotine & Tobacco Research, 05/21/2012
Ferketich AK et al. – In this preliminary study, the safety profile of varenicline among HIV–infected smokers resembles findings among smokers without HIV. In addition, varenicline may be more effective at promoting abstinence in this population.Methods
- Participants completed 12 weeks of telephone counseling and either varenicline or NRT.
- Varenicline was encouraged as the preferred intervention; NRT was used for those unable/unwilling to take varenicline.
- Adverse events (AEs), related to pharmacotherapy, were monitored.
- Biochemically confirmed abstinence at 3 months was examined.
- Inverse probability of treatment weighted logistic regression models was fit to compare participants on varenicline to those on NRT.
- Among participants on varenicline (n = 118), the most common AEs were nausea, sleep problems, and mood disturbances.
- One person reported suicidal ideation; there were no cardiovascular complications.
- There were no differences in the varenicline AE profile between participants on combination antiretroviral therapy (ART) and those not on ART.
- The percentages of confirmed abstainers were 11.8% in the NRT group and 25.6% in the varenicline group.
- The odds of being abstinent were 2.54 times as great in the varenicline group compared with the NRT group in the propensity weighted model (95% CI 1.43–4.49).